Kelun-Biotech's Lung Cancer Drug Trial Meets Primary Endpoint
MT Newswires Live
Jul 15
Sichuan Kelun-Biotech Biopharmaceutical's (HKG:6990) phase 3 study of sacituzumab tirumotecan (sac-TMT) combined with Merck's Keytruda met the primary endpoint in first-line treatment of PD-L1-negative advanced non-squamous non-small cell lung cancer, according to a Wednesday Hong Kong bourse filing.
The study showed the combination significantly improved progression-free survival compared with pembrolizumab plus chemotherapy.
An interim analysis also indicated a positive trend in overall survival, while no new safety signals were identified.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.